Blueprint Medicines (BPMC) Misses Q3 EPS by 5c

Blueprint Medicines (NASDAQ: BPMC) reported Q3 EPS of ($0.96), $0.05 worse than the analyst estimate of ($0.91).

For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.

You May Also Be Interested In

• Ennis (EBF) Reports In-Line Q1 EPS
• Goldman Sachs Upgrades China Resources Microelectronics Ltd (688396:CH) to Neutral
• Middleby board approves spin-off of food processing unit Midera